We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Privacy Terms and Cookie Policy
Shining Light on Farm & Food Policy for 20 Years.
Sunday, November 24, 2024
CBD products are marketed almost everywhere these days, and hemp farmers are counting on this new, emerging market to bolster their revenues. However, the U.S. Food and Drug Administration (FDA) is stepping up its warnings on CBD in dietary supplements and food products
President Donald Trump announces his intent to nominate Finch Fulton to assistant secretary of Transportation and Tas Smith has joined the National Cotton Council.
House and Senate negotiators will have to sort through some sharply different priorities and spending targets for USDA and other departments and agencies important to agriculture.
The Senate is looking to finish work on a package of spending bills funding USDA and other agencies important to agriculture, but it increasingly appears that Congress won’t reach a final agreement on fiscal 2020 until after the first of the year.
Senate Republicans are moving a fiscal 2020 spending bill for the Agriculture Department that tees up a fight with House Democrats over the relocation of two USDA research agencies to the Kansas City region.
House Democratic leaders are aiming to push through a stopgap spending bill this week after threatening a fight with the White House, and potentially with some of their own rural members, over a plan that could jeopardize farmers’ trade aid payments.
Farmers should join the enthusiasm about industrial hemp’s huge potential, ranging from medicinal uses to bioplastics, chemicals, fuels, paper and bioremediation – but proceed with caution.
All three of the federal agencies charged with regulating bioengineered plants and animals are looking at ways of streamlining regulations and smoothing the path to commercialization for gene-edited traits.
Last week, the Food and Drug Administration (FDA) responded to calls from our community to reconsider its role in regulating gene editing technology in animal agriculture. Despite the Trump administration’s recent directive to streamline costly and overly burdensome regulations that inhibit innovation and investment, FDA maintains it is unwilling to cede any regulatory control of this important technology.
